Neurology · DepressionRegulatory Approvalregulatorymid-term

FDA Acceptance of Supplement for AUVELITY by AXSOME

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/11/2026, 6:31:38 PM

Assessment confidence: 88% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of the supplemental application for AUVELITY is a significant regulatory milestone that could strengthen AXSOME's market position in the competitive depression treatment landscape. This development necessitates close monitoring of the approval timeline and its potential impact on competitors. Regulatory context from FDA (FDA AP — AUVELITY (SUPPL)) supports the near-term read. Assessment grounded in 7 ranked evidence items (7 high-relevance).

Strategic Assessment

Portfolio teams should assess the implications of this supplement on AXSOME's market strategy and potential competitive advantages. The strongest clinical anchor is Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (ClinicalTrials.gov), sponsor/company relevance (merck). In rare disease, 7 regulatory and 0 competitive items passed relevance filtering for AXSOME.

Competitive Pressure

The most relevant competitive pressure comes from This acceptance may enhance AXSOME's position in the depression treatment market, potentially impacting competitors with similar indications..

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — AUVELITY (SUPPL) (FDA). Sub-indication match (rare disease); Entity match (axsome). The acceptance of the supplemental application indicates a positive step towards potential approval, but the final outcome remains uncertain and will require ongoing observation.

Key Risks

Elevated medium regulatory exposure for AXSOME could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If approved, AUVELITY could capture additional market share in the depression treatment sector, impacting revenue streams for both AXSOME and its competitors.
Portfolio teams should assess the implications of this supplement on AXSOME's market strategy and potential competitive advantages.

What Would Change This Assessment

This becomes more urgent if Monitor the timeline for the FDA's review process and any subsequent announcements regarding approval outcomes.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — AUVELITY (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Entity match (axsome)
FDA document
View source
Learning and Education to ADvance and Empower Rare Disease Drug Developers (LEADER 3D)
FDAhigh relevance
Sub-indication match (rare disease)
FDA document
View source
FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG)
FDAhigh relevance
Sub-indication match (rare disease)
FDA document
View source
FDA AP — BUTORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease)
FDA document
View source
FDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease)
FDA document
View source
FDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease)
FDA document
View source
FDA AP — BUTORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease)
FDA document
View source

Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
ClinicalTrials.govlow relevance
Sponsor/company relevance (Merck)
FDA document
View source
Characterization and Treatment of Adolescent Depression
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Post-Market Clinical Evaluation of the Treatment of Femur Fractures With the Femoral Nail GT
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
CONNECT Cancer Survivors With Tobacco Treatment
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

FDA Accepts BLA for Langlara by Sunshine Lake Pharma
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities
FDA Approves Supplemental Application for RINVOQ LQ by AbbVie
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Microneedle-based injection of Fungizone/Amphotericin B: an effective treatment for American cutaneous leishmaniasis in mice.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Adaption of a posttraumatic stress disorder intervention for patients who use stimulants and opioids in the opioid treatment programme setting.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

AXSOME
AUVELITY
depression treatment market

Commercial impact

medium

If approved, AUVELITY could capture additional market share in the depression treatment sector, impacting revenue streams for both AXSOME and its competitors.

Regulatory impact

medium

The acceptance of the supplemental application indicates a positive step towards potential approval, but the final outcome remains uncertain and will require ongoing observation.

What to watch

Monitor the timeline for the FDA's review process and any subsequent announcements regarding approval outcomes.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.